Screening and identification of hub genes in bladder cancer by bioinformatics analysis and KIF11 is a potential prognostic biomarker.

bioinformatics analysis biomarker bladder cancer kinesin family member 11

Journal

Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 31 07 2020
accepted: 18 12 2020
entrez: 12 2 2021
pubmed: 13 2 2021
medline: 13 2 2021
Statut: ppublish

Résumé

Bladder cancer (BC) is the ninth most common lethal malignancy worldwide. Great efforts have been devoted to clarify the pathogenesis of BC, but the underlying molecular mechanisms remain unclear. To screen for the genes associated with the progression and carcinogenesis of BC, three datasets were obtained from the Gene Expression Omnibus. A total of 37 tumor and 16 non-cancerous samples were analyzed to identify differentially expressed genes (DEGs). Subsequently, 141 genes were identified, including 55 upregulated and 86 downregulated genes. The protein-protein interaction network was established using the Search Tool for Retrieval of Interacting Genes database. Hub gene identification and module analysis were performed using Cytoscape software. Hierarchical clustering of hub genes was conducted using the University of California, Santa Cruz Cancer Genomics Browser. Among the hub genes, kinesin family member 11 (KIF11) was identified as one of the most significant prognostic biomarkers among all the candidates. The Kaplan Meier Plotter database was used for survival analysis of KIF11. The expression profile of KIF11 was analyzed using the ONCOMINE database. The expression levels of KIF11 in BC samples and bladder cells were measured using reverse transcription-quantitative pCR, immunohistochemistry and western blotting. In summary, KIF11 was significantly upregulated in BC and might act as a potential prognostic biomarker. The present identification of DEGs and hub genes in BC may provide novel insight for investigating the molecular mechanisms of BC.

Identifiants

pubmed: 33574944
doi: 10.3892/ol.2021.12466
pii: OL-0-0-12466
pmc: PMC7816288
doi:

Types de publication

Journal Article

Langues

eng

Pagination

205

Informations de copyright

Copyright: © Mo et al.

Références

Bioinformatics. 2011 Feb 1;27(3):431-2
pubmed: 21149340
Novartis Found Symp. 2002;247:91-101; discussion 101-3, 119-28, 244-52
pubmed: 12539951
Brief Bioinform. 2019 May 21;20(3):778-788
pubmed: 29272324
J Clin Oncol. 2006 Feb 10;24(5):778-89
pubmed: 16432078
Cell Cycle. 2018;17(4):486-491
pubmed: 29251172
Genome Biol. 2007;8(9):R183
pubmed: 17784955
Mol Carcinog. 2013 Nov;52(11):871-8
pubmed: 22692973
BMC Syst Biol. 2014;8 Suppl 4:S11
pubmed: 25521941
Cancer Res Treat. 2019 Jul;51(3):1207-1221
pubmed: 30590004
Nucleic Acids Res. 2002 Jan 1;30(1):207-10
pubmed: 11752295
Int J Oncol. 2018 Jan;52(1):155-165
pubmed: 29115586
Cancer Res. 2004 Jun 1;64(11):4040-8
pubmed: 15173019
J Clin Pathol. 2019 May;72(5):354-362
pubmed: 30819726
Urol Oncol. 2019 Dec;37(12):900-906
pubmed: 31597600
Urol Oncol. 2016 May;34(5):237.e1-10
pubmed: 26706119
Transl Androl Urol. 2020 Apr;9(2):153-165
pubmed: 32420122
Methods Mol Biol. 2016;1368:3-4
pubmed: 26614064
Nucleic Acids Res. 2013 Jan;41(Database issue):D808-15
pubmed: 23203871
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
J Clin Oncol. 2010 Jun 1;28(16):2660-7
pubmed: 20421545
Clin Cancer Res. 2013 Apr 1;19(7):1717-28
pubmed: 23403633
Clin Genitourin Cancer. 2017 Aug;15(4):450-454
pubmed: 27842896
Cell Mol Biol (Noisy-le-grand). 2016 Mar 20;62(3):25-30
pubmed: 27064870
Cancers (Basel). 2019 Apr 15;11(4):
pubmed: 30991738
Proc Natl Acad Sci U S A. 2020 Jan 7;117(1):563-572
pubmed: 31871155
Genome Res. 2002 Jun;12(6):996-1006
pubmed: 12045153
Bioinformatics. 2005 Aug 15;21(16):3448-9
pubmed: 15972284
Nat Genet. 2006 Dec;38(12):1386-96
pubmed: 17099711
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
EMBO Mol Med. 2020 Jan 9;12(1):e10880
pubmed: 31709755
J Cardiovasc Magn Reson. 2012 Nov 30;14:83
pubmed: 23199362
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Pathobiology. 2017;84(1):16-24
pubmed: 27459100
Front Physiol. 2018 Apr 18;9:399
pubmed: 29720944
J Cell Sci. 1998 Sep;111 ( Pt 17):2551-61
pubmed: 9701554
Cancer Sci. 2010 Jun;101(6):1501-10
pubmed: 20345479

Auteurs

Xiao-Cong Mo (XC)

State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China.
Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China.

Zi-Tong Zhang (ZT)

State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China.
Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China.

Meng-Jia Song (MJ)

State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China.
Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China.

Zi-Qi Zhou (ZQ)

State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China.
Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China.

Jian-Xiong Zeng (JX)

State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China.
Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China.

Yu-Fei Du (YF)

State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China.
Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China.

Feng-Ze Sun (FZ)

State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China.
Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China.

Jie-Ying Yang (JY)

State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China.
Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China.

Jun-Yi He (JY)

State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China.
Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China.

Yue Huang (Y)

State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China.
Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China.

Jian-Chuan Xia (JC)

State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China.
Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China.

De-Sheng Weng (DS)

State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China.
Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China.

Classifications MeSH